Developing the next generation of miniaturized continuous glucose monitors (CGM) with Dexcom
What is the Miniaturized CGM program?
We’ve partnered with Dexcom to minimize the size and cost of continuous glucose monitors (CGMs) to make them more accessible to more people. CGM is the current standard of care for people with type 1 diabetes, and is becoming increasingly relevant for people with type 2 diabetes who want to control their diabetes with timely, actionable information. People with type 2 diabetes who are enrolled in Verily’s Onduo program may receive the Dexcom G6 as a seamless and connected way to gain daily insight into their blood glucose levels and help drive behavioral activation. We’ve developed miniaturized electronics for the investigational Dexcom G7, which will be the smallest CGM to date. Dexcom will be conducting pivotal studies for the G7 in order to secure regulatory approval.
How are you making it happen?
Traditional glucose monitoring methods are cumbersome and monitoring may be infrequent, but with a CGM, consistent and continuous data provides valuable insights to help individuals better manage their own disease. Our hardware engineering team has built miniaturized sensor electronics on an adhesive patch to make continuous and accurate monitoring less disruptive. Smaller and more comfortable CGMs may replace finger sticks in people with type 2 diabetes, and have the potential to increase behavioral compliance and adherence to treatment regimens.
The miniaturized CGM patch is designed to enable continuous subcutaneous monitoring of the interstitial fluid that may be less burdensome for those required to measure their glucose levels. The CGM patch will have wireless connectivity for secure data sharing and easy tracking of continuous glucose levels.
See our findings via the American Diabetes Association.